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In the science of toxicology, the fundamental
goal is to understand the effects of both sin-
gle chemicals and mixtures of chemicals on
biological systems and, in doing so, to allow
the assessment of human health risks associ-
ated with exposure. To accomplish this task,
toxicologists have modeled the toxic response
as consisting of both pharmacokinetic and
pharmacodynamic elements (Figure 1).
Pharmacokinetics is a description of the
distribution, metabolism, and excretion of
a chemical, including its metabolites.
Pharmacokinetics can be used to predict the
ultimate dose of the toxic moiety at the site
of action. In contrast, pharmacodynamics is
a description of how tissues respond to the
chemical once it gets there. These responses
can include cell death, adaptation, differenti-
ation, or proliferation and can include any
manifestation of the toxic response in the
whole organism. However, toxicology is at
the beginning of a transition that is being
driven by an explosion in the amount of
genomic sequence information available and
the fast-paced development of technologies
to exploit its use. As a result, the science of
toxicology is compelled to reanalyze its tradi-
tional models and incorporate this new
knowledge.
Although the traditional model of toxicity
has been used primarily in a descriptive man-
ner by linking chemical doses at the site of
action with tissue pathology, system-level tox-
icity, and overt mortality, the model is still
valid and useful as a framework for under-
standing chemical toxicity. To keep pace with
the current progress in biological research, the
foundation of this model has shifted from
descriptive observations to a mechanistic
understanding of toxicity at the molecular
level. Genomic information is central to this
type of molecular understanding and under-
lies both the pharmacokinetic as well as the
pharmacodynamic aspects of the model.
For example, the genomic sequence (i.e.,
genotype) of an individual can significantly
affect the pharmacokinetics for a particular
chemical, thereby determining the individ-
ual’s susceptibility to toxicity via changes in
the target tissue dose (1,2). In addition, gene
expression can change rapidly and dramati-
cally in response to chemical exposure, and
these changes are responsible for many of the
pharmacodynamic effects.
Like biology, the foundation of toxicology
is predicated on the sequence of our genome,
and it also underlies many of our current con-
ceptual models of how chemicals produce tox-
icity. Therefore, the integration of genomics
into toxicological research is essential as we
search to understand how various chemicals
and the corresponding mixtures act in the
human body and to develop better tools to
assess the risks associated with exposure. With
the sequencing of the human genome nearly
completed (3,4) and significant progress on
the mouse and rat models, the integration of
genomics into toxicology on even a greater
scale can become reality.
Application of Genomics 
to Toxicity Testing
In our current regulatory and public heath
environment, chemicals that are thought to
have the potential for a significant level of
human exposure and to pose potential heath
risk are selected to undergo subsequent testing
for toxicity and carcinogenic potency. The tra-
ditional method of evaluating carcinogenic
activity and chronic toxicity of a speciﬁc chem-
ical has been the two-year animal bioassay.
The experimental design for these studies
involves animals of both sexes and usually
from one strain of rat and/or mice. Several
dosage levels are chosen, with approximately
50 animals per sex per dose level. The high
dose corresponds to the maximum tolerated
dose (MTD) as determined in short-term or
subchronic toxicity studies and can be based
on a variety of end points, including target
organ pathology, changes in body weight, and
adverse clinical signs. The intermediate dose
selection is usually a function of the high dose
(e.g., half the MTD), and the spacing between
doses is often determined by the conﬁdence in
the prediction of the end point used to derive
the high dose selection (5). The experimental
protocol includes detailed records on animal
health, vital statistics, and pathology. Because
of the cost- and labor-intensive nature of these
studies, each bioassay costs between $2 and $4
million and takes several years to complete (6).
According to the U.S. National Toxicology
Program (NTP), the number of chemicals cur-
rently tested by the NTP stands at 505 in
long-term studies, 66 in short-term tests, and
only a single subchronic study (7). Given that
there are between 70,000 to 85,000 chemicals
in commerce today (8,9), it is clearly impossi-
ble to apply current testing methodologies to
all chemicals of concern, let alone the corre-
sponding mixtures (Figure 2). It is apparent
that alternative testing approaches must be
developed if science is to maintain a signiﬁcant
role in environmental and public health policy.
The development of an efﬁcient screening
process that would allow prioritization of
untested chemicals and mixtures based on
their toxic potential would signiﬁcantly affect
how efficiently we evaluate both synthetic
and naturally occurring compounds. One
approach for predicting toxic potential is to
classify chemicals based on their capacity to
alter transcriptional programs in a manner
similar to that of known toxicants or chemi-
cals already tested in the two-year bioassay.
Test chemicals that induce transcriptional
responses in a manner similar to those
induced by an established toxicant could then
be classified as harboring toxic potential.
These chemicals could be examined carefully
by more thorough toxicological means and
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subjected to interim regulations until they are
proven safe. By taking this approach, one
would have to make one overriding assump-
tion—that most, if not all, toxic chemical
exposures will alter gene expression at some
level. In support of this assumption, toxicity
by its very nature results from some form of
cellular dysfunction or cell death that will
result in changes in gene expression at some
level. These changes can be associated either
with the root cause of the toxicity or down-
stream of the initial event. Nonetheless, the
resulting overall pattern of gene expression
changes can act as a diagnostic “ﬁngerprint”
for that chemical to match with known toxi-
cants or chemicals already tested in the two-
year bioassay.
The widespread application of microarray
technology to toxicity testing would require
the integration of sophisticated statistical tools
into the analysis. Speciﬁcally, the use of statisti-
cal classiﬁcation techniques would be necessary
to build predictive models for the subsequent
classiﬁcation of unknown/untested chemicals.
These statistical techniques range from linear
and nonlinear discriminant analysis (10) to
Bayesian classiﬁcation (11), nearest-neighbor
approaches (12), and neural networks (13).
With any of these techniques, a training data
set is needed in which the model is trained on
data where the answer is already known. For
example, a potentially beneﬁcial data set could
come from a subset of the compounds already
bioassayed by the NTP. These compounds
could be fed to small numbers of rodents in
short-term studies and the changes in gene
expression evaluated using microarray technol-
ogy. Provided that the subset of chemicals con-
tains chemicals that show both positive and
negative results in the bioassay, a classiﬁcation
model could be built to predict the response
with subsequent untested chemicals. The accu-
racy of these predictions could be evaluated
using additional cross-validation techniques
(14) and the results used to make critical
regulatory decisions about the safety of the
analyzed compounds.
The application of microarray analysis and
statistical classification tools to the type of
chronic toxicity study outlined above has the
potential to be extremely useful from both a
scientific and an economic perspective. This
type of study would allow the construction
and validation of a statistical model based on
gene expression patterns that would predict the
long-term toxicity of an unknown chemical
based on short-term rodent studies using only
a small number of animals. The potential sav-
ings in cost and time could be immense, and
the current gap between the number of tested
and untested chemicals could be reduced in
the interest of public health. However, there
are signiﬁcant hurdles to overcome before this
type of analysis will be useful on a large scale.
First, multiple factors converge to ultimately
inﬂuence the manifestation of toxicity and the
associated gene expression patterns. Among
these factors are time, dose, route of adminis-
tration, age of the animal, and sex. Fully char-
acterizing the inﬂuence of all of these variables
on transcript proﬁles with even a small number
of treatments would require considerable
resources (e.g., 500 treatments × 3 time points
per treatment × 3 doses per time point × 3
routes per dose × 3 ages per treatment × 2
sexes × 3 tissues = 243,000 microarray studies). 
Conceptually, some of these variables
could be standardized in the animal studies
and, in principle, the classification models
incorporate a number of these variables
because the models statistically relate gene
expression measurements performed in a
short-term study to the results from the two-
year bioassay. Whether the classification
models will be robust enough to allow accu-
rate predictions despite these factors remains
to be seen. Second, the training set must be
carefully chosen to incorporate a broad spec-
trum of toxicants that act via different mecha-
nisms. The ability of the statistical model to
predict long-term toxicity of a chemical that
differs signiﬁcantly from the training set will
be limited. Therefore, the larger the public
database of chemically induced gene expres-
sion and the more toxicological categories
added to the model, the more predictive the
models will become. Although some progress
is being made toward classifying chemical
toxicants based on gene expression patterns
(11,15,16), many of these hurdles still exist.
However, toxicogenomics will continue to
advance, and the era of the resource-intensive
animal bioassay will undoubtedly end.
Application of Genomics 
to Species Extrapolation
It is well established that most known human
chemical carcinogens are also carcinogenic in
at least one species of laboratory animal.
Whether the reverse is true cannot, and prob-
ably will never, be established with any degree
of conﬁdence. However, the assumption that
it is true provides part of the foundation for
toxicological testing in animal systems and is
the basis for one of the underlying principles
in toxicology—that experimental results in
animal models, given certain restrictions, are
generally applicable to humans. Regulatory
agencies, academic researchers, pharmaceuti-
cal companies, and chemical companies all
rely heavily on results from animal studies for
establishing health and safety guidelines,
assessing toxicity, and evaluating the potential
efficacy of new drugs. For example, animal
studies are commonly used at the U.S.
Environmental Protection Agency (U.S.
EPA) in both the hazard identification and
response assessment phases of the risk assess-
ment process. During hazard evaluation, the
U.S. EPA evaluates a chemical’s inherent tox-
icity using laboratory animal models (i.e., the
type and extent of harmful effects), and the
response assessment includes additional
dose–response and chronic exposures to ﬁnd
the no-observed-effect level (NOEL) and cal-
culate a reference dose (RfD). Although addi-
tional safety factors are built into calculating
the RfD, the basis for its calculation relies on
results from the animal studies.
Despite the heavy reliance on animal
models in toxicological research, most toxi-
cologists recognize that significant quantita-
tive and qualitative differences exist between
humans and the animal models used in toxi-
cological research. For example, there are sig-
nificant differences in the responses of
rodents and humans to peroxisome prolifera-
tors (17), and the lethal dose for 2,3,7,8-
tetrachlorodibenzo-p-dioxin varies by more
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Figure 1. The traditional model of toxicity encom-
passing a number of quantitative and qualitative
characteristics that fall into two categories—
pharmacokinetics and pharmacodynamics.
Pharmacokinetics is described as what the body
does to the chemical via fate and distribution.
Pharmacodynamics is described as what the
chemical does to the body and how the body
responds. These responses can include cell death,
adaptation, differentiation, or proliferation that lead
to the manifestation of the toxic response in the
whole organism. Both pharmacokinetics and phar-
macodynamics are integrated to link the dose of
the chemical at the site of action with the response
of the tissue, thereby providing a basis for estimat-
ing the risk of human exposure.
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Figure 2. A comparison between the estimated
number of chemicals in commerce and the number
of chemicals tested in chronic animal bioassays by
the NTP. Estimates of the number of chemicals in
commerce were derived from previously published
reports (8), and the number of chemicals tested
was obtained from the NTP website (7). Based on
the current rate of testing, it is apparent that the
number of chemicals tested will never approach
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than 1,000-fold between species (18). With
these examples and many others, it is evident
that the identiﬁcation of toxicological species
differences and their implementation in the
regulatory arena are essential from both a
health and economic standpoint. To do this,
a clear understanding of both the pharmaco-
kinetic and pharmacodynamic differences
between species is necessary. For the pharma-
cokinetics, studies of the fate and distribu-
tion of the chemical in each species can be
performed, and the application of biologi-
cally based models to this type of data has
proven useful for species extrapolations (19).
For the pharmacodynamics, the identifica-
tion can be more challenging, particularly
without a molecular understanding of the
chemical’s action. It is here that the applica-
tion of genomics can identify cross-species
differences at the molecular level.
The development of a system that would
allow the assessment of all molecular differ-
ences between species after chemical exposure
would have a significant impact on how we
evaluate the pharmacodynamic aspects of
cross-species extrapolations. Although assessing
all molecular differences is nearly impossible,
one approach for assessing these differences is
to measure transcriptional alterations in orthol-
ogous sets of genes (i.e., genes in different
species that evolved by speciation from a com-
mon ancestral gene; Figure 3). Test chemicals
that induce different transcriptional responses
between species could then be classiﬁed as har-
boring potential pharmacodynamic differ-
ences. These chemicals could be examined
carefully on a mechanistic basis and subjected
to additional regulatory review. By taking this
approach, one would have to make two
assumptions. First, for many chemicals,
in vitro results from human cell types would
have to be similar to those obtained in vivo
because of obvious limitations on human stud-
ies. Second, conserved changes in gene expres-
sion equate to conserved pharmacodynamic
end points. For the ﬁrst point, arguments for
and against extrapolating from in vitro results
to in vivo predictions are important but will
not be addressed here. In support of the sec-
ond assumption, evolution and selection have
maintained the structure and function of many
biochemical pathways over time, resulting in
the conservation of many important processes
(20). Although the function of some genes
may have changed over time, similar changes
in orthologous sets of genes are likely to pro-
duce the same physiological end point whether
it is inflammation, proliferation, apoptosis,
necrosis, or cellular differentiation.
To develop a system that can exhaustively
measure alterations in orthologous genes, the
majority of the genomic sequence of both
species must be known and the sequences
compared in order to identify evolutionarily
conserved coding regions. For toxicology, this
would mean the completion of the mouse
(currently at 96% in both draft and ﬁnished
sequence), rat (currently at 64% in both draft
and ﬁnished sequence), and human genomes
(currently at 98% in both draft and ﬁnished
sequence). Previous studies have already com-
pared large segments (>30 kb) of human and
rodent sequences, demonstrating that coding
domains are generally well conserved, whereas
noncoding regions exhibit variable levels of
conservation (21). After completion of the
genomes, the sequences could be compared
using various sequence alignment algorithms
and the results screened for coding potential
(i.e., containing an open reading frame over
the length of the conserved sequence). The
resulting list would contain orthologous sets
of putative exons that could be used to create
parallel rodent and human microarrays.
The application of genomics to species
extrapolation issues in the form of cross-
species sequence comparisons and ortholo-
gous microarray analysis has the potential to
provide critical molecular data on the ways
different species react to toxicants. This type
of analysis would allow the integration of
both pharmacokinetic information and phar-
macodynamic information at a basic level and
significantly improve the uncertainty associ-
ated with conventional risk assessments.
Fundamentally, this issue is at the root of
both biological and toxicological research. It
is also tied to large amounts of money in
terms of research dollars and Superfund-
related cleanup costs, and it forms the basis
for the protection of human health from
chemical exposure. As a result, the use of
genomic information of this type should be
leveraged in toxicology to its fullest extent.
Application of Genomics to
Understanding Mechanism
Although related to chemical classification
and cross-species extrapolation, the identiﬁca-
tion of toxic mechanism based on gene
expression is a unique problem with unique
challenges. The primary difficulties are reli-
ably detecting subtle changes in gene expres-
sion (i.e., <2-fold) that may be biologically
relevant, assigning functional significance to
any observed alterations, and separating
downstream transcriptional changes from the
causative changes. These problems are not
just related to toxicology but also include the
microarray ﬁeld as a whole.
To reliably detect subtle changes in gene
expression, technology and associated statisti-
cal methods must continue to advance in
order to evaluate these potentially important
transcriptional changes. However, there are
obvious limits to what this or any other tech-
nology can detect in biological samples, and
assessing potential changes that are less than
the natural biological variability may be
impossible. One potential solution to this
problem is to separate the affected cell popu-
lation from the surrounding normal tissue
using microdissection (22). Using this tech-
nique, transcriptional alterations can be iden-
tified that would have normally gone
undetected when analyzing the tissue as a
whole.
To assign functional significance to
observed changes in gene expression, various
statistical methods have been used together
with multiple experimental conditions in order
to group genes according to common expres-
sion patterns. These methods include self-orga-
nizing maps (23), support vector machines
(24), k-means (25), and hierarchical clustering
techniques (26). The underlying assumption
of the clustering approach is that genes chang-
ing in a coordinate fashion are functionally
related, and if these changes correspond to the
onset of toxicity, they may be mechanistically
involved. Although there are many assump-
tions and data gaps in this type of analysis,
genes with similar function do tend to be coor-
dinately expressed. However, the link to toxic
mechanism is much more tenuous, and it has
not yet proved to be the proverbial silver bullet
for understanding the mechanism of action for
a particular treatment.
In less complex organisms, other
approaches have proven useful for under-
standing and assigning signiﬁcance to speciﬁc
gene expression patterns. For example, the
analysis of gene expression changes in yeast
deletion mutants together with chemical
treatments has allowed the identification of
previously unidentiﬁed targets for commonly
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Figure 3. A flow chart describing the construction
of orthologous microarrays to address critical
species extrapolation issues in toxicology. From
the top of the flow chart, the available genome
sequences of both humans and the important
rodent models are used to identify evolutionary
conserved regions. These regions are screened for
coding potential and arrayed on glass slides.
Measurements of gene expression in both organ-
isms after chemical insult will allow the evaluation
of conserved pharmacodynamic end points.used drugs (27). Although the experiment
with the yeast deletion mutants was relatively
ideal because of the compound chosen and
the complexity of the model system, the
application of these types of techniques
toward the understanding of toxic mecha-
nisms in mammalian systems shows promise.
A recent estimate of the number of genes in
the human genome is approximately 35,000
(3,4), and the rodent has even less. As a
result, the systematic screening of various
gene subsets could potentially be a reality
provided that there is access to large numbers
of in vivo or in vitro deletion mutants or an
equivalent knockdown technology. A few
emerging techniques show promise in this
area. In particular, application of small inter-
fering RNAs (siRNAs) in mammalian cell
culture has the potential to provide a knock-
down system on a genomewide scale (28).
Despite the potential of these types of
experiments, they are not currently feasible for
many toxicological microarray investigations.
For some investigators, classic protein synthesis
inhibitors have been used to separate primary
and secondary effects (29). However, despite
the apparent separation of these effects, the
authors were still unable to arrive at a mecha-
nism for the chemical and concluded that the
biological mechanism was more complicated
than previously imagined. For many treat-
ments in our laboratory, a similar conclusion
was reached, and it has become apparent that
our understanding of what a particular gene
expression change means biologically and how
these patterns relate to a phenotype is limited
at best. Thus, the application of arrays for
understanding the mechanism of chemical tox-
icity may not yet be achievable given our cur-
rent set of experimental tools and our present
understanding of the biology involved.
Although the potential ability to measure
global patterns of gene expression and
instantly understand how an unknown chem-
ical produces toxicity is an exciting possibil-
ity, this problem may prove to be the most
difﬁcult to solve in the near future because it
relies on an intricate knowledge of the biolog-
ical system being altered, and alterations at
the transcriptional level may account for only
a subset of the toxic responses. However, the
field of genomics is progressing fast, and we
are accumulating knowledge at an ever-
increasing pace. Databases of gene expression
are appearing, and studies of well-character-
ized toxicants are adding to our understand-
ing. As a result, this ability to make these
comparisons may become reality as our
knowledge base continues to grow.
Application of Genomics 
to Susceptibility Prediction
The conceptual model of toxicology outlined
in the introductory paragraphs views the
etiology of the toxic response resulting from
chemical exposure as a complex mix of phar-
macokinetic and pharmacodynamic factors
with an underlying genetic component. Part
of this genetic component is the variability of
the individual organism at the nucleotide
level of the gene. Variations in a predominant
allele are usually referred to as genetic poly-
morphisms, a term used to describe variation
at an incidence of >1%. Of these changes,
single nucleotide polymorphisms (SNPs) are
the most common between individuals and
are thus the primary affective agent in pheno-
typic variation. The frequency of polymor-
phism in humans is approximately one SNP
per 1,000 bases of DNA, and currently more
than 1.42 million SNPs have been identiﬁed
across the human genome by the SNP
consortium alone (30).
Although the majority of these polymor-
phisms have no consequences, a small subset
can have dramatic effects on gene function,
leading to a variety of phenotypic responses.
As a result, the identiﬁcation and characteriza-
tion of these polymorphisms have become
important in both the pharmaceutical indus-
try and environmental toxicology. For exam-
ple, in the pharmaceutical industry, a
significant number of approved drugs have
serious side effects not detected before
approval and lead to approximately 100,000
deaths per year in the United States (31).
These undiscovered side effects are due pri-
marily to the heterogeneity of the human pop-
ulation and the relatively small number of
patients in clinical trials, which therefore do
not identify small, susceptible populations.
From a public health perspective, the 100,000
deaths per year is roughly equivalent to the
number of automobile fatalities in the United
States in 1999 (32). Financially, if the phar-
maceutical company has to pull the drug, it
may experience losses as high as $500 million,
not including potential lawsuits.
The identification and characterization
of toxicologically relevant SNPs are difficult
problems for a number of reasons, including
their low relative frequency, problems in
relating polymorphisms to function, and the
sheer number of potential genes directly or
indirectly involved in a particular toxicologi-
cal phenotype. In general, polymorphisms
that alter gene function do so in several
ways. First, the change produces an amino
acid substitution that alters protein stability,
function, or activity. Second, the variation
occurs in the regulatory region, which alters
the rate of transcription. Third, the change
produces a premature termination of the
protein. Fourth, the variant produces
changes in RNA stability or splicing.
Relating these changes to function and
human health consequences is the next
big step and usually includes molecular
epidemiologic methods, functional in vitro
assays, and animal models (33).
The molecular epidemiologic approaches
are difficult because of issues such as dose
reconstruction and confounding variables
such as concurrent exposure to other chemi-
cals (i.e., chemical mixtures). The in vitro
studies can also be difficult to interpret
because of the relevance of in vitro results for
in vivo end points. However, combining the
two approaches provides both a mechanistic
characterization of the polymorphism and rel-
evance to the in vivo condition that will have
a higher probability of success. In addition,
identification of polymorphisms in model
organisms will also prove to be important to
the identification of relevant human SNPs.
There are a significant number of chemicals
in the environment that we know little or
nothing about, and using the differential sen-
sitivities of the various mouse strains will help
map out important loci related to chemical
toxicity as well as chemical carcinogenesis.
Despite the inherent difficulties with each
approach, SNPs located in toxicologically
pertinent genes will most likely be uncovered
through highly directed sequencing efforts
focusing on these allelic differences (34). This
type of sequencing effort, together with epi-
demiologic and functional in vitro analysis, is
currently being undertaken at the U.S.
National Institutes of Environmental Health
Sciences with the Environmental Genome
Project (35).
Understanding human susceptibility to
exposure is at the heart of all toxicology.
Clinical, environmental, and industrial toxi-
cologists all deal with susceptible subpopula-
tions, and the resulting variation in toxic
responses can be large enough to warrant
pulling a drug off the market or to lead to
unpredictable debilitating diseases such as
Gulf War syndrome. It is only by identifying
these subpopulations that we can educate
them on the various risks they may face.
Although this also carries with it tremendous
ethical implications, this application of
genomics to toxicology has the potential to
personalize the risk assessment process and
tailor it for the genotype of the individual.
Conclusions
Although the study of genes and their impact
on toxicity has been around for a number of
years, the recent progress in genome sequenc-
ing and the ability to simultaneously monitor
the expression of thousands of genes have
moved genomics to the forefront of toxicology
and spurred the coining of the term toxicoge-
nomics. The near completion of the human
genome and the progress on the rodent
sequencing mark a new era not just in biology
but in toxicology as well. However, the avail-
ability of the sequence information and the
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only part of the effort. The integration of this
information and application to problems such
as toxicity testing, cross-species extrapolation,
and susceptibility is the goal of the future and
where some of the true benefits of these
advancements lie. This will be true for both
single chemical exposures and chemical mix-
tures that may have additive, greater than
additive, or antagonistic effects on the assessed
molecular end points.
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